CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Opzelura (ruxolitinib) cream coverage — topical JAK inhibitor (Atopic Dermatitis, Vitiligo)

Policy governs prior authorization, coverage criteria, quantity limits, and continuation rules for topical ruxolitinib (Opzelura) cream for dermatologic indications for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyOpzelura (ruxolitinib) cream coverage — topical JAK inhibitor

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization documenting age ≥12, dermatologist/allergist involvement, BSA 3%–20%, non‑immunocompromised status, and prior topical therapy failures.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization duration

≥12minimum age

3%–20%eligible BSA

60 g/30 daysquantity limit

Nonsegmental vitiligoexcluded indication

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial therapy for Atopic Dermatitis

Authorization of 12 months may be granted when ALL of the following are met:

Initial AD criteria: A. Member is 12 years of age or older

Prescriber: B. Medication is prescribed by, or in consultation with, a dermatologist or allergist/immunologist

Diagnosis and BSA: C. Diagnosis of mild to moderate atopic dermatitis with affected body surface area (BSA) of 3% to 20%; documentation of affected areas and affected BSA is provided3% to 20%

Immunocompetence: D. Member is not immunocompromised

Topical corticosteroid trial: E. Documentation that the member experienced an inadequate treatment response to at least one medium to super-high potency topical corticosteroid for at least 2 consecutive weeks; contraindications, adverse effects, and/or intolerance must be documented>=2 weeks

Formulary topical agent trial: F. Documentation that the member experienced an inadequate treatment response to one of the following formulary topical drugs: tacrolimus ointment for 6 consecutive weeks, pimecrolimus cream for 6 consecutive weeks, or Eucrisa (crisaborole) ointment for 4 consecutive weeks; contraindications, adverse effects, and/or intolerance must be documented6 weeks or 4 weeks per agent

Topical anti-inflammatory trial: G. Documentation that the member experienced an inadequate treatment response to Zoryve cream 0.15% for 4 weeks or Vtama cream 1% for 8 weeks; contraindications, adverse effects, and/or intolerance must be documented4 weeks or 8 weeks

Continuation of therapy

Authorization of 12 months may be granted for continuation when ALL of the following are met:

Clinical response: A. Documentation that member has achieved or maintained a positive clinical response evidenced by low disease activity (i.e., clear or almost clear skin) or clinical improvement in signs and symptoms of AD (e.g., improvement in pruritus, redness)

Concomitant therapy restriction: B. Opzelura will not be used concomitantly with Eucrisa (crisaborole) ointment, Vtama (tapinarof) cream, Zoryve (roflumilast) cream, any therapeutic biologic drug, any targeted synthetic drug, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine

Use of Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo is an excluded benefit and is not covered for cosmetic purposes.

Any use of Opzelura for indications other than the ones explicitly listed in this policy (atopic dermatitis and nonsegmental vitiligo) is considered experimental/investigational and is not medically necessary.

Prescriber and prior authorization requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for treatment of Atopic Dermatitis (AD). Authorization of up to 12 months may be granted when all clinical criteria are met.

Member age ≥ 12 years
Prescribed by or in consultation with a dermatologist or allergist/immunologist
Member is not immunocompromised

Step Therapy

Step Therapy Requirements for AD

Step therapy must be documented prior to approval for AD. Member must have inadequate response, intolerance, or contraindication to required topical therapies.

Inadequate response to at least one medium to super-high potency topical corticosteroid for ≥2 consecutive weeks (or documented contraindication/intolerance)
Inadequate response to one of: tacrolimus ointment (6 consecutive weeks), pimecrolimus cream (6 consecutive weeks), or Eucrisa (crisaborole) ointment (4 consecutive weeks)
Inadequate response to Zoryve cream 0.15% for 4 weeks or Vtama cream 1% for 8 weeks

Documentation Required

Documentation Requirements

Document the affected body surface area (BSA) and specific affected areas as part of the prior authorization request. For AD approvals, BSA must be 3%–20%. Include clinical notes supporting inadequate response, adverse effects, contraindications, or intolerance to prior therapies.

Document affected BSA (must be between 3% and 20%)
Document the specific affected areas of the body
Provide documentation of inadequate response, adverse effects, or contraindications to prior therapies

Denial Risk

Nonsegmental Vitiligo — Excluded Benefit

Opzelura is indicated for topical treatment of nonsegmental vitiligo, but use for this indication is an excluded benefit for cosmetic purposes and is not covered.

Nonsegmental vitiligo treatment is not a covered benefit (cosmetic)

Definitions and key terms

Non-immunocompromised

Required patient statusMember must be non-immunocompromised to be eligible for Opzelura

Age linkageNon-immunocompromised requirement applies alongside the minimum age criterion (≥12 years)

Clinical implicationOpzelura indicated for topical short-term and non-continuous chronic treatment in non-immunocompromised patients

Affected body surface area (BSA) — documentation

Required BSA for coverageAffected body surface area must be documented as between 3% and 20% for covered atopic dermatitis treatment

Documentation elementsProvider must supply documentation of affected areas and the calculated affected BSA

Policy applicationBSA requirement is part of the initial authorization criteria for 12 months for mild to moderate AD